Amalgamated Financial’s Celldex Therapeutics CLDX Stock Holding History

Amalgamated Financial’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$241K	Buy	+7,080	New	+$226K	﹤0.01%	1827

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Amalgamated Financial's CLDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Celldex Therapeutics (CLDX) in Q1 2022: 7,080 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings.

168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

Amalgamated Financial held 7,080 shares of Celldex Therapeutics worth $241K as of Q1 2022.
Celldex Therapeutics was a new Amalgamated Financial position in Q1 2022.
Celldex Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1827 holding.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.